Schreiber R, Lewis C, Crane K. Patient Assessment of Foam Attributes from the Tazarotene Foam, 0.1%, Phase III Trials and Potential Impact on Patient Compliance. J of Skin [Internet]. 2018 Dec. 17 [cited 2024 Jul. 3];2:S57. Available from: https://jofskin.org/33014/index.php/skin/article/view/455